BRAF and melanoma: Because our results showed that HAT1-knockdown and HAT1-KO BRAFi-resistant melanoma cells demonstrated increased IGF1R expression levels and increased MAPK pathway activation, we examined whether the ERK inhibitor SCH77298436 or the IGF1R inhibitor BMS-75480737 could resensitize HAT1-knockdown and HAT1-KO BRAFi-resistant melanoma cells to BRAF inhibitor vemurafenib.